Eduovisual
Special Senses & Otolaryngology
Acute hearing loss: sudden sensorineural workup
— Unilateral in >90% of cases; bilateral SSNHL is rare and raises suspicion for autoimmune, vascular, or systemic etiology.
— Incidence ~5–27 per 100,000/year; peak in adults age 43–53; either sex.
— Patient reports "sudden deafness," muffled hearing, or aural fullness on awakening.
— Accompanying tinnitus (~80%) and/or vertigo (~30–40%).
— Failure to hear on one side during phone use ("phone-ear" complaint).
— Recent URI, loud noise exposure, head trauma, ototoxic medication, or new neurologic symptoms.
Step 3 management: A patient calling the clinic with new unilateral muffled hearing should be triaged in today, not scheduled in 2–4 weeks. The single most cost-effective intervention for SSNHL is time-to-audiogram and time-to-steroid. AAO-HNS 2019 guidelines explicitly recommend against routine head CT and routine broad lab panels; the diagnostic anchor is the audiogram, not imaging or serology.
Board pearl: If tuning fork tests point conductive (Weber lateralizes to affected ear, Rinne BC>AC), it is not SSNHL — look for cerumen impaction, effusion, or TM perforation instead.
— Onset over seconds to minutes → vascular (cochlear stroke, vertebrobasilar event) until proven otherwise.
— Onset over hours to 3 days → typical idiopathic SSNHL pattern.
— Onset over weeks → think vestibular schwannoma or autoimmune inner ear disease (cycles of loss with partial recovery).
— Tinnitus (very common, prognostically neutral).
— Vertigo or imbalance — negative prognostic sign, suggests broader labyrinthine involvement.
— Aural fullness ("plugged ear" — patients and clinicians often misattribute to Eustachian dysfunction, delaying diagnosis).
— Otalgia, otorrhea, fever → think otitis media/externa, not SSNHL.
— Neurologic: diplopia, dysarthria, facial weakness, ataxia → posterior fossa lesion or AICA territory stroke.
— Recent URI or viral prodrome.
— Loud acoustic trauma (concert, gunfire, airbag).
— Barotrauma (flight, diving) → consider perilymphatic fistula.
— Head or temporal bone trauma.
— Medications: aminoglycosides, cisplatin/carboplatin, high-dose loop diuretics, NSAIDs, sildenafil (rare association).
— Tick exposure (Lyme), STI history (syphilis), autoimmune disease (Cogan, GPA, SLE).
— Family history of hearing loss, prior episodes (Meniere disease).
— Bilateral simultaneous loss.
— Fluctuating loss with episodic vertigo and aural fullness → Meniere.
— Progressive asymmetric loss over months → schwannoma.
— Focal neurologic deficits → stroke workup.
Key distinction: Patients frequently describe SSNHL as "my ear feels plugged." Do not anchor on Eustachian tube dysfunction without a tuning fork exam and otoscopy — this is the most common reason for missed or delayed SSNHL diagnosis on Step 3 stems and in real practice. Document exact onset time; it drives treatment urgency and prognosis.
— Clear external canal — rule out cerumen impaction, foreign body, otitis externa.
— Intact, mobile TM without effusion, retraction, perforation, or cholesteatoma.
— Pneumatic otoscopy: normal TM mobility; Hennebert sign (vertigo/nystagmus with insufflation) suggests perilymphatic fistula or superior canal dehiscence.
— Weber: Place on forehead/vertex. In SSNHL, sound lateralizes to the unaffected (better) ear. In conductive loss, it lateralizes to the affected (worse) ear.
— Rinne: AC > BC bilaterally in sensorineural loss (a "positive" Rinne on the affected side). BC > AC indicates conductive loss of ≥25 dB.
— Combined pattern of Weber lateralizing away from the symptomatic ear + bilateral AC>BC = consistent with SSNHL → expedite audiogram.
— CN V, VII, VIII function — schwannomas can produce facial numbness/weakness or corneal reflex loss.
— Nystagmus characterization: peripheral (horizontal-torsional, suppressed by fixation) vs central (vertical, direction-changing, not suppressed).
— HINTS exam in patients with vertigo: Head Impulse normal, direction-changing Nystagmus, Test of Skew positive → central lesion, activate stroke pathway.
— Gait, finger-to-nose, heel-to-shin, Romberg.
— Skin: vesicles in the ear canal/auricle = Ramsay Hunt (VZV), often with facial palsy; this is otologic herpes zoster, not idiopathic SSNHL.
— Eyes: interstitial keratitis → Cogan syndrome.
— Joints/skin: suggest autoimmune etiology.
— Vital signs: hypertension, AF on pulse — vascular risk factors.
CCS pearl: On the CCS-style approach, order otoscopic exam, tuning fork tests, full neurologic exam, and audiometry before any imaging or labs. A patient with vertigo + SSNHL-pattern hearing loss and an abnormal HINTS exam should be sent to the ED immediately — AICA infarcts can present exactly this way and the cochlear deficit may be the only "extra" clue beyond classic posterior circulation stroke.
— Diagnostic threshold: ≥30 dB sensorineural loss across ≥3 contiguous frequencies compared with the unaffected ear (or with prior audiogram if available).
— Patterns: low-frequency loss (Meniere-like, often better prognosis), mid-frequency "cookie-bite" (genetic), high-frequency loss (noise, presbycusis, ototoxicity), and profound flat loss (worse prognosis).
— Type A tympanogram expected; type B/C suggests middle ear effusion → conductive contribution, not SSNHL.
— Absent ipsilateral acoustic reflexes with present contralateral reflexes may localize to retrocochlear pathology.
— Word recognition scores disproportionately poor relative to pure-tone average → retrocochlear lesion (e.g., vestibular schwannoma).
— Targeted serologies only when clinically indicated:
— RPR/VDRL or treponemal test — syphilis is a treatable, reversible cause; many experts still test routinely given low cost and high stakes.
— Lyme serology in endemic exposure history.
— ANA, ANCA, ESR if autoimmune features (Cogan, GPA, SLE).
— TSH if other thyroid signs.
— HIV if risk factors.
Board pearl: The AAO-HNS 2019 update strongly recommends against ordering routine head CT and against routine laboratory testing in suspected idiopathic SSNHL. The high-value, evidence-based workup is audiogram + targeted history + MRI for retrocochlear evaluation. Step 3 frequently tests recognition that ordering "a CT head and a metabolic panel" first is the wrong move — get the audiogram and start steroids.
— Indication: confirmed SSNHL to evaluate for retrocochlear pathology, even when classic idiopathic features are present.
— Yield: vestibular schwannoma in ~2–4% of SSNHL patients; also detects multiple sclerosis plaques, AICA infarct, meningeal disease, labyrinthitis (enhancement of cochlea/vestibule).
— Timing: ideally within weeks of diagnosis, but treatment must not be delayed waiting for MRI.
— Alternative when MRI contraindicated (pacemaker, severe claustrophobia, body habitus).
— Less sensitive than MRI for small (<1 cm) schwannomas.
— Videonystagmography (VNG), video head impulse test (vHIT), VEMP — reserved for persistent vertigo or atypical course.
— Bilateral SSNHL → CBC with diff, ESR, CRP, ANA, ANCA, RF, RPR, HIV; consider hypercoagulable workup; otolaryngology and rheumatology referrals.
— Suspected autoimmune inner ear disease (AIED): rapidly progressive bilateral SSNHL over weeks to months, response to steroids supports diagnosis. There is no single confirmatory blood test — diagnosis is clinical/therapeutic.
— Suspected perilymphatic fistula: temporal bone CT, possibly exploratory tympanotomy by ENT.
— Suspected superior semicircular canal dehiscence: high-resolution temporal bone CT.
— Obtain at completion of steroid course (2–6 weeks) and again at 6 months to document recovery and counsel about hearing aids/cochlear implant candidacy.
Step 3 management: When a 50-year-old completes a steroid course for SSNHL and partially recovers, the next best step is MRI IAC with gadolinium, not "reassurance and follow-up in a year." Missing a vestibular schwannoma is the most common diagnostic-omission pitfall. If MRI shows a schwannoma, refer to neurotology/neurosurgery for observation, radiosurgery, or microsurgical resection based on size, growth rate, and hearing status.
— Favorable: younger age, mild–moderate loss, low-frequency or mid-frequency pattern, no vertigo, early treatment, upsloping audiogram.
— Unfavorable: profound or flat severe loss, downsloping high-frequency pattern, vertigo, older age (>65), delayed presentation, comorbid diabetes/vascular disease.
— Spontaneous recovery occurs in ~30–65% of untreated idiopathic SSNHL — but you cannot identify those patients prospectively, so treat all.
— Step 1: Confirm sensorineural pattern (tuning forks, otoscopy normal).
— Step 2: Order urgent audiogram (same day if possible, within 14 days otherwise).
— Step 3: Initiate oral corticosteroids as soon as SSNHL is suspected, even before audiogram if the test will be delayed >24–48 hours and clinical suspicion is high.
— Step 4: Refer to otolaryngology for consideration of intratympanic (IT) steroid injection as primary therapy or salvage.
— Step 5: Order MRI IAC with contrast to evaluate for retrocochlear pathology.
— Step 6: Repeat audiometry at the end of treatment and at 6 months.
— Discuss the natural history, the modest evidence base for steroids (number needed to treat ~5–7 for meaningful recovery), risks of steroids, and the option of combined oral + intratympanic therapy.
CCS pearl: On a CCS case, the correct sequence is: focused H&P → tuning fork → audiogram → start prednisone → schedule MRI → otolaryngology consult → repeat audiogram in 2 weeks. Avoid the trap of ordering broad labs, CT head, or antibiotics — these score against you and delay therapy. If vertigo with central HINTS findings, divert to stroke protocol instead.
— Prednisone 1 mg/kg/day (max 60 mg) PO daily for 10–14 days, then taper over 5–10 days.
— Alternative: methylprednisolone 48–64 mg/day or dexamethasone 10 mg/day equivalent.
— Start within 2 weeks of symptom onset; earlier is better. Do not delay to await audiogram if access is limited.
— Take with food in the morning to mimic diurnal cortisol pattern and reduce insomnia.
— Dexamethasone 24 mg/mL or methylprednisolone 40 mg/mL injected through TM, typically 3–4 injections over 2 weeks.
— Used as: (1) primary therapy in patients who cannot tolerate systemic steroids (diabetes, peptic ulcer, severe psychiatric disease, pregnancy concerns); (2) combined therapy with oral steroids (some evidence of additive benefit, especially in severe loss); (3) salvage therapy within 2–6 weeks if oral steroids fail to restore hearing.
— Adverse effects: transient otalgia, vertigo, persistent TM perforation (~1–2%), rare otitis media.
— Hyperglycemia (warn diabetic patients to check sugars more frequently; may need temporary insulin uptitration).
— Insomnia, mood changes, increased appetite.
— GI upset; consider PPI if high risk.
— Avoid live vaccines during therapy.
— Avoid abrupt discontinuation if used >2 weeks.
— Antivirals (acyclovir, valacyclovir) — no benefit unless Ramsay Hunt.
— Thrombolytics, vasodilators, vasoactive substances.
— Hyperbaric oxygen — optional adjunct if started within 3 months, especially within 2 weeks, in patients with moderate–severe loss; available at limited centers.
Board pearl: A diabetic patient with SSNHL who cannot tolerate systemic steroid-induced hyperglycemia is the classic stem for intratympanic dexamethasone as primary therapy — same efficacy as oral with no systemic glucose effect. Do not withhold treatment because of diabetes.
— Performed in ENT office under topical anesthesia (phenol or lidocaine) of the posterior-inferior TM quadrant.
— Patient supine, head turned, ear up; injectate fills middle ear and bathes the round window membrane.
— Patient remains still for 20–30 minutes without swallowing to allow steroid absorption through the round window.
— Series: typically 3–4 injections spaced 3–7 days apart over 2 weeks.
— Salvage IT therapy can be offered up to 6 weeks after onset for incomplete responders to oral steroids, with documented benefit even at the late edge of the window.
— Mechanism: increases oxygen tension in perilymph, potentially reversing cochlear hypoxia.
— AAO-HNS: may offer as adjunct within 2 weeks (strongest data) or up to 3 months.
— Typical protocol: 10–20 sessions at 2.0–2.5 ATA for 90 minutes.
— Limited by access, cost, insurance, and contraindications (untreated pneumothorax, certain chemo agents).
— Hearing aids for residual moderate–severe loss after 6 months.
— CROS/BiCROS aids for single-sided deafness — route sound from deaf ear to better ear.
— Bone-anchored hearing implants (BAHA) for single-sided deafness.
— Cochlear implantation for severe-to-profound single-sided or bilateral deafness; growing indication for SSD-cochlear implant with documented benefit in sound localization and tinnitus.
— Counseling on natural decrescendo, sound enrichment/masking, cognitive behavioral therapy.
— Avoid benzodiazepines for tinnitus; treat comorbid anxiety/depression appropriately.
Step 3 management: A patient 5 weeks out from SSNHL onset with only 50% recovery after a complete oral steroid course is the stem for referral to ENT for salvage intratympanic steroids. Do not write off the hearing as permanent at this point — salvage IT therapy still offers meaningful benefit through ~6 weeks. After 6 months of stable residual loss, transition to rehabilitation (CROS, BAHA, or cochlear implant evaluation).
— SSNHL prognosis is worse with advancing age; treat aggressively within the window regardless.
— Higher risk of steroid-induced complications: hyperglycemia, hypertension exacerbation, delirium, osteoporosis flare, infection susceptibility, sleep disturbance.
— Check baseline blood pressure and glucose before initiating prednisone; monitor weekly during therapy.
— In frail elderly or those on chronic anticoagulation with high steroid risk, intratympanic steroid monotherapy is an attractive option — no systemic exposure.
— Be alert for medication interactions: prednisone potentiates warfarin (monitor INR), and concurrent NSAIDs increase GI bleeding risk in elderly patients.
— Screen for and address presbycusis on the unaffected ear after recovery; bilateral functional impairment substantially affects falls risk and cognition.
— Prednisone metabolism is hepatic, not renal — no dose adjustment for CKD.
— Watch volume retention and BP escalation, particularly in CKD stages 3–5.
— Avoid concurrent NSAIDs (already a relative contraindication in CKD); use acetaminophen for ear discomfort.
— Consider IT steroid route to bypass systemic effects in advanced CKD.
— Prednisone requires hepatic conversion to prednisolone; in severe liver disease, prednisolone is preferred (equipotent, no first-pass conversion needed).
— Monitor for fluid overload, encephalopathy worsening, and infection risk in cirrhotic patients.
— Anticipate 20–80 mg/dL rise in glucose with prednisone 60 mg/day.
— Counsel home glucose monitoring 4×/day; uptitrate insulin or add prandial coverage as needed.
— IT steroid monotherapy avoids systemic glycemic disruption; strongly consider in poorly controlled DM (A1c >9%).
— Short steroid courses (≤2–3 weeks) carry minimal bone density impact, but address calcium/vitamin D intake.
Key distinction: Older age and diabetes both worsen SSNHL prognosis and increase steroid risk — this is precisely the population where intratympanic dexamethasone earns its place as primary therapy, not as salvage. Step 3 stems often pair a "67-year-old with type 2 diabetes" with SSNHL to test this judgment.
— SSNHL in pregnancy is uncommon but reported; consider preeclampsia-related vascular phenomena in late pregnancy.
— Prednisone is category C but generally considered acceptable for short courses; <10% crosses the placenta after maternal first-pass metabolism. Use lowest effective dose for shortest duration.
— Avoid use in first trimester if possible (small association with orofacial clefts in older data); if SSNHL occurs in first trimester, discuss risk/benefit and strongly consider intratympanic steroid as primary therapy.
— MRI without gadolinium is safe in pregnancy; gadolinium is generally avoided (especially first trimester) — defer contrast MRI postpartum or after delivery unless urgently needed.
— Prednisone is compatible with breastfeeding; <1% maternal dose reaches the infant. Some recommend waiting 4 hours after dose before nursing for very high doses.
— Rare but real; consider congenital cytomegalovirus reactivation, mumps, meningitis sequelae, enlarged vestibular aqueduct (consider after minor head trauma), and Lyme disease.
— Audiometry techniques are age-appropriate (visual reinforcement, conditioned play, ABR for infants).
— Steroid dosing: prednisolone 1 mg/kg/day (max 60 mg) for 10–14 days.
— MRI with sedation may be needed; involve pediatric otolaryngology early.
— Always evaluate for nonaccidental trauma when temporal bone fracture or unexplained otologic findings present in young children.
— Higher index of suspicion for opportunistic infections (CMV, HIV, syphilis, cryptococcal, Lyme).
— Coordinate steroid use with infectious disease specialist if active infection.
— Inquire about barotrauma; suspect perilymphatic fistula in divers with SSNHL after a dive — surgical exploration may be indicated.
Board pearl: A pregnant patient in the first trimester with SSNHL is the classic exam stem for intratympanic dexamethasone as preferred primary therapy — equivalent efficacy to oral, negligible systemic absorption, minimal fetal exposure. Document shared decision-making and coordinate with maternal-fetal medicine.
— ~30–35% of treated patients have minimal or no recovery.
— Single-sided deafness (SSD) impairs sound localization, speech-in-noise comprehension, and social/occupational function.
— Bilateral functional impairment accelerates cognitive decline (independent risk factor for incident dementia per Lancet Commission), increases social isolation, depression, and falls risk in older adults.
— Affects 70–80% of SSNHL patients long-term to varying degrees.
— Associated with anxiety, depression, sleep disruption, suicidality (in severe cases — screen with PHQ-9).
— Treatments: sound therapy, hearing aids (when applicable), cognitive behavioral therapy, tinnitus retraining therapy.
— Persistent imbalance or chronic dizziness in ~30% of those with vertigo at onset.
— Vestibular rehabilitation therapy is the mainstay; refer to PT with vestibular specialization.
— Oral corticosteroids: hyperglycemia, hypertension, insomnia, mood disturbance, GI upset, peptic ulcer, immune suppression, avascular necrosis (rare with short courses), osteoporosis.
— Intratympanic injection: transient vertigo, otalgia, ~1–2% persistent TM perforation (may require myringoplasty), rare otitis media or labyrinthitis.
— Hyperbaric oxygen: barotrauma, oxygen toxicity, claustrophobia.
— Depression, anxiety, occupational disability (especially in musicians, teachers, healthcare workers, lawyers, call-center workers).
— Driving safety concerns with directional hearing loss.
— Untreated vestibular schwannoma may grow, causing brainstem compression, hydrocephalus, or facial nerve injury.
— Missed posterior circulation stroke is a major medicolegal pitfall.
Step 3 management: At every SSNHL follow-up, screen for depression (PHQ-9), tinnitus distress, falls, and occupational impact. Refer for audiologic rehabilitation if loss persists ≥3 months and to mental health services if PHQ-9 ≥10 — SSNHL is psychologically corrosive, and primary care must own this longitudinal piece.
— SSNHL plus any central neurologic sign (vertical nystagmus, dysarthria, diplopia, ataxia, facial droop, hemiparesis, abnormal HINTS) → activate stroke pathway. AICA territory infarcts classically present with SSNHL + vertigo + ipsilateral facial palsy.
— SSNHL plus severe headache, neck stiffness, fever → rule out meningitis.
— SSNHL plus recent significant head trauma → CT temporal bones, neurosurgery and ENT consults; consider temporal bone fracture.
— All confirmed or strongly suspected idiopathic SSNHL cases — for intratympanic steroid candidacy, audiometric coordination, and follow-up.
— Suspected perilymphatic fistula (post-barotrauma vertigo with fluctuating loss).
— Suspected Meniere flare with persistent profound loss.
— Persistent or partial hearing loss after steroid course for rehabilitation planning, hearing aid evaluation, or cochlear implant assessment.
— MRI showing vestibular schwannoma — coordinate with neurotology.
— Suspected multiple sclerosis (younger patient, optic neuritis history, other CNS symptoms, demyelinating lesions on MRI).
— Recurrent or bilateral SSNHL of unclear etiology.
— Bilateral or sequential SSNHL with systemic autoimmune features (Cogan, GPA, SLE, RA).
— Suspected autoimmune inner ear disease unresponsive to steroids — for biologic or steroid-sparing therapy.
— Positive syphilis, Lyme, HIV, or other infectious serologies requiring specialized management.
— Significant tinnitus distress, depression, anxiety, or suicidality.
CCS pearl: Do not "manage and observe" SSNHL in primary care alone. Even when you initiate prednisone, you must place a same-week ENT referral and order MRI — the CCS scoring favors simultaneous parallel action: start the drug, place the consult, schedule the imaging, and arrange the follow-up audiogram in one visit.
— Conductive loss (Weber to affected ear, BC>AC). Visible on otoscopy. Resolves with cerumen removal.
— Conductive loss, type B tympanogram, dull/retracted TM. Often follows URI; usually resolves spontaneously.
— Conductive loss with pain, fever, bulging erythematous TM. Treat per IDSA guidelines.
— Conductive loss after trauma, barotrauma, or infection. Visible perforation.
— Progressive conductive loss with chronic otorrhea, retraction pocket or keratin debris on otoscopy. CT temporal bone confirms.
— Progressive (not sudden) conductive or mixed loss in young adults, often bilateral, with normal TM. Schwartze sign (pink TM). Audiogram shows Carhart notch at 2 kHz.
— Episodic vertigo (20 min to 12 hr) + fluctuating low-frequency sensorineural loss + tinnitus + aural fullness. Recurrent attacks differentiate from SSNHL; however, the first attack can mimic SSNHL.
— Typically slowly progressive asymmetric SNHL with tinnitus and disproportionate word recognition decline; can present as SSNHL in ~10%. MRI IAC with gadolinium confirms.
— Acute viral inflammation; vestibular neuritis has vertigo without hearing loss; labyrinthitis has both vertigo and SNHL.
— VZV reactivation: vesicles in ear canal, facial palsy, otalgia, SNHL, vertigo. Treat with acyclovir/valacyclovir plus steroids.
— Recent loud exposure (concert, gunfire, airbag). Often 4 kHz notch. Acute exposure can mimic SSNHL pattern.
— Aminoglycosides, cisplatin, loop diuretics (usually transient), salicylates (usually transient), vancomycin (controversial).
Key distinction: Meniere's first attack can look identical to SSNHL on day one. Distinguish over time: recurrent vertigo-hearing-fullness episodes with low-frequency loss = Meniere; single event of stable severe SNHL = idiopathic SSNHL.
— AICA infarct — SSNHL + vertigo + facial palsy + ipsilateral Horner ± ataxia. Cochlea is supplied by the labyrinthine artery (branch of AICA). Order MRI with diffusion-weighted imaging if neuro signs present.
— Vertebrobasilar insufficiency — transient hearing loss with brainstem symptoms.
— Microvascular cochlear ischemia is hypothesized in idiopathic SSNHL among older patients with vascular risk factors.
— Multiple sclerosis — rarely presents with SSNHL; consider in younger patients with other CNS signs (optic neuritis, sensory symptoms, INO). MRI brain reveals plaques.
— Syphilis (otosyphilis) — can present at any stage; treat with IV penicillin + steroids; always consider because it is treatable and easily missed.
— Lyme disease — endemic exposure; can cause cranial neuropathies including CN VIII.
— HIV — both acute seroconversion and AIDS-associated opportunistic infections can cause SNHL.
— Congenital CMV reactivation in pediatric populations.
— Bacterial meningitis sequelae — usually post-meningitis SNHL, sometimes presenting acutely.
— Autoimmune inner ear disease (AIED) — rapidly progressive bilateral SNHL over weeks to months; steroid-responsive.
— Cogan syndrome — interstitial keratitis + audiovestibular dysfunction; rheumatology consult.
— GPA, SLE, RA, sarcoidosis, Susac syndrome (encephalopathy + branch retinal artery occlusions + SNHL).
— Vestibular schwannoma, meningioma, leptomeningeal carcinomatosis, endolymphatic sac tumor (von Hippel-Lindau).
— Severe hypothyroidism, diabetes (chronic association more than acute), uncontrolled hypertension.
— Temporal bone fracture, barotrauma, perilymphatic fistula, acoustic trauma.
— Rare but real; inconsistent audiogram results, normal ABR.
Board pearl: Always test for syphilis in unexplained SSNHL even when "classic idiopathic" picture — otosyphilis is treatable, the test is cheap, and the legal/clinical consequences of missing it are severe. Bilateral SSNHL particularly demands broad infectious and autoimmune workup.
— Complete prescribed 10–14-day course + 5–10-day taper (e.g., prednisone 60 mg ×10 days, then 40 mg ×3, 20 mg ×3, 10 mg ×3, stop).
— Counsel not to abruptly stop if course is ≥2 weeks (HPA suppression risk).
— Strict noise protection: foam earplugs (NRR 29 dB) or earmuffs in workplace, concerts, power tools, firearms.
— Limit headphone use; 60/60 rule (≤60% volume, ≤60 min at a time).
— Annual or semiannual audiograms to monitor for progression or contralateral involvement.
— Caution with aminoglycosides, cisplatin, high-dose loop diuretics, high-dose NSAIDs, salicylates. Discuss alternatives with prescribers when feasible.
— Notify all future providers of SSNHL history.
— Hypertension, diabetes, dyslipidemia, smoking cessation — observational data link vascular health to hearing trajectory.
— Apply USPSTF and ACC/AHA guidelines for primary prevention.
— Single-sided deafness: discuss CROS hearing aid, BAHA, or cochlear implant options after 3–6 months of persistent loss.
— Bilateral loss: hearing aid fitting; cochlear implant evaluation if severe-to-profound.
— Sound enrichment (white noise, fans, hearing aids with maskers), CBT, tinnitus retraining therapy. Avoid chronic benzodiazepine use.
— Screen PHQ-9 and GAD-7 at each visit for the first 6 months; refer or treat as indicated.
— Discuss directional hearing limitations; review occupational exposure modifications with employer/occupational health if relevant.
Step 3 management: SSNHL is not a one-and-done diagnosis. The long-term plan includes annual audiometry, hearing protection counseling, vascular risk factor management, and rehab — the same longitudinal framework Step 3 expects for any chronic sensory deficit.
— End of steroid course (2–3 weeks): clinical assessment, repeat audiogram, decide salvage IT steroid candidacy.
— 6 weeks post-onset: final window for salvage therapy; reassess audiogram.
— 3 months: assess for recovery plateau; initiate rehabilitation discussions.
— 6 months: definitive audiogram; rehabilitation device fitting if residual loss.
— Annually thereafter: monitor contralateral ear (small risk of bilateral SSNHL), screen for recurrence, manage tinnitus and mental health.
— Home glucose log in diabetic patients (4×/day).
— Blood pressure at 1 week if hypertensive.
— Screen for mood/sleep disturbance.
— Caution and counsel about infection risk; live vaccines deferred during therapy.
— Annual surveillance MRI for "watch-and-wait" approach to small (<1.5 cm) tumors; growth >2 mm/yr usually prompts intervention.
— Discuss realistic expectations: hearing aids restore audibility, not perfect clarity; CROS systems improve awareness but not directionality; cochlear implants for SSD improve sound localization and tinnitus more than speech recognition.
— Encourage family communication strategies: face speaker, reduce background noise, use captioning.
— Connect with assistive devices: amplified phones, vibrating alarm clocks, smoke detectors with strobes.
— Support groups: HLAA (Hearing Loss Association of America).
— If persistent imbalance, refer to vestibular PT — gaze stabilization, balance retraining, habituation exercises.
— ADA accommodations for workplace (FM systems, captioning, modified phones, sign language interpreters if applicable).
— Document for disability evaluation if appropriate.
— Early intervention services, IEP/504 plan coordination with school district, speech-language therapy.
Board pearl: A patient with persistent profound SSD 6 months after a SSNHL event is the stem for cochlear implant referral — Medicare and most insurers now cover CI for adult SSD, and outcomes data show meaningful improvement in localization, tinnitus suppression, and quality of life.
— SSNHL is among the top otologic malpractice claims, predominantly for delayed diagnosis and missed treatment window. Documentation of symptom onset, tuning fork results, audiometry timing, and steroid initiation is essential.
— Telephone triage protocols must flag "sudden hearing loss" as a same-day complaint. Train front-desk and triage nurses accordingly — a patient told to "wait 4 weeks for an audiology slot" who loses recovery potential is a defensible plaintiff.
— Discuss the modest evidence base (NNT ~5–7), spontaneous recovery possibility, adverse effects, and intratympanic alternative. Document shared decision-making.
— For intratympanic steroid injection, discuss TM perforation risk (~1–2%), transient vertigo, and the off-label nature of the medication.
— Closed-loop referral: confirm ENT appointment is scheduled within days, not weeks. If your local ENT cannot accommodate, initiate prednisone yourself and document the rationale.
— Ensure MRI is ordered (not just discussed) and results are reviewed — tracking systems for incidental schwannomas are a known safety gap.
— Pediatric SSNHL with suspicious history (e.g., temporal bone injury, repeated trauma) → mandated child abuse reporting.
— Workplace acoustic trauma → OSHA reporting and workers' compensation documentation.
— Counsel patients with new single-sided deafness about adjusted driving habits (extra mirror use, reduced left-side phone use).
— Use ADA-compliant communication: face patient, ensure adequate lighting, provide written instructions, offer interpreter services for sign language users.
— Avoid the assumption that "speaking louder" addresses sensorineural loss — clarity, not volume, is the issue.
— Audiology access, MRI access, and hearing aid affordability (often not covered by Medicare without supplemental plans) create disparities. Connect patients to low-cost OTC hearing aid options (FDA-approved 2022 for mild-moderate loss) and state assistance programs.
— MRI may reveal incidental aneurysms, pituitary lesions, or white matter disease. Establish a workflow for review, disclosure, and follow-up.
Step 3 management: Document onset date, time to steroid initiation, audiogram date, MRI order, ENT referral date, and shared decision-making in every SSNHL visit note — this is both the standard of care and a defensive medical-legal record.
Board pearl: If you remember only one thing: audiogram + prednisone + MRI + ENT, all within 2 weeks. That sequence answers most Step 3 questions on this topic correctly.
— "A 50-year-old woman wakes with right ear muffled hearing, tinnitus, and aural fullness. Otoscopy normal. Weber lateralizes to left, Rinne AC>BC bilaterally. Next step?"
— Answer: Pure-tone audiometry (then prednisone).
— "Audiogram confirms 45 dB SNHL across 500–4000 Hz on the right, normal left ear. What is the most appropriate next step?"
— Answer: Oral prednisone 60 mg daily for 10–14 days (do not wait for MRI to start steroids).
— Distractors include CT head, antibiotics, antivirals, lipid panel, ENG, audiology referral in 4 weeks. The correct answer rejects routine CT and labs in favor of audiogram + steroids.
— "67-year-old with type 2 diabetes (A1c 8.9) presents with SSNHL. Most appropriate therapy?"
— Answer: Intratympanic dexamethasone as primary therapy (avoids hyperglycemia).
— "Patient completed 14-day prednisone course; repeat audiogram shows minimal improvement at 5 weeks. Next step?"
— Answer: Salvage intratympanic steroid injection (effective up to ~6 weeks).
— "Audiogram shows asymmetric SNHL with disproportionately poor word recognition. Next step?"
— Answer: MRI IAC with gadolinium (suspect vestibular schwannoma).
— "Sudden hearing loss with vertigo, vertical nystagmus, and unsteady gait." → MRI brain with DWI and stroke pathway, not steroids first.
— Ear canal vesicles + facial palsy + SNHL → acyclovir + prednisone.
— SSNHL in a patient with multiple sexual partners or HIV → RPR/treponemal testing; treat with IV penicillin if positive.
— Toddler with new hearing loss and unexplained bruising → child abuse evaluation and mandated report, in addition to ENT.
— Single-sided deafness 6 months post-SSNHL → CROS aid, BAHA, or cochlear implant evaluation.
— PHQ-9 score 14, persistent tinnitus → CBT + SSRI, not benzodiazepine.
Key distinction: When stems include "head CT" or "broad lab panel" as options for isolated SSNHL with classic features, those are wrong-answer distractors. The right path is always audiogram-first, steroid-second, MRI-third.
Sudden sensorineural hearing loss is an otologic emergency: confirm with same-day audiometry, start high-dose oral corticosteroids within 2 weeks, and order MRI IAC with gadolinium to evaluate for retrocochlear pathology — never delay treatment for imaging or labs.
Board pearl: The single most testable concept on this topic is time-to-steroid and time-to-audiogram — the family physician's job is to recognize, act, and refer simultaneously rather than sequentially. A "sudden hearing loss" phone call must be triaged into clinic the same day.
Step 3 management: Always document onset date, tuning fork findings, audiogram result, steroid start time, MRI order, and ENT referral in the chart — this single workflow captures both the clinical standard of care and the medicolegal record, and it answers virtually every Step 3 vignette on this topic correctly.